Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin, Decitabine, and Venetoclax in Acute Myeloid Leukemia
NCT03041688Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navtemadlin in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoint: Incidence of toxicity up to 4 weeks. Started Feb 2018; status: active, not recruiting.
02
Drugs
navtemadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03041688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041688.